Idi na sadržaj

Onkologija (pedijatrija)

Klinički ishodi

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. (otvara se novi prozor)

Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R

Izvor‎: J Clin Oncol 2014;32(27):3021-32.

Indeks‎: PubMed 25092781

DOI‎: 10.1200/JCO.2014.55.3628

https://www.ncbi.nlm.nih.gov/pubmed/25092781 (otvara se novi prozor)

Red blood cell transfusion and outcome in cancer. (otvara se novi prozor)

Iqbal N, Haider K, Sundaram V, Radosevic J, Burnouf T, Seghatchian J, Goubran H

Izvor‎: Transfus Apher Sci 2017;56(3):287-90.

Indeks‎: PubMed 28602484

DOI‎: 10.1016/j.transci.2017.05.014

https://www.ncbi.nlm.nih.gov/pubmed/28602484 (otvara se novi prozor)

Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases. (otvara se novi prozor)

Oh SY, Kim SH, Kwon HC, Lee S, Kim KH, Kwon KA, Lee JH, Lee KY, Kim HJ

Izvor‎: Support Care Cancer 2010;18(10):1341-6.

Indeks‎: PubMed 19841950

DOI‎: 10.1007/s00520-009-0759-3

https://www.ncbi.nlm.nih.gov/pubmed/19841950 (otvara se novi prozor)